CRI’s Center for Biologics Research and Development (CBRD) was founded with the intention to bridge the gap between drug development at laboratory scale and the clinical use, i.e., from bench to bedside. The development of biologics starts from the generation of cell line that produced biologics of interest, product. characterization, proof of the efficacy in vitro and in vivo, toxicity testing, and clinical studies. The process development and scale up to the production of biologics for clinical use with GMP-compliance is also an important step in the drug development.
The ultimate goal of CBRD is to improve the quality of life of Thai people by enabling accessibility and affordability to high quality biotherapeutics. The disease scope includes cancers, infectious diseases, and rare diseases. The first success case is the development of trastuzumab biosimilar from basic cell line engineering to pilot scale production and preclinical (animal) study. The production scale and clinical study are in the process. Another goal of CBRD is to be a training center for biopharmaceutical industry for CGI students as well as external researchers who interested to re-skill and up-skill in this arena. Collectively, CBRD contributes a supportive role in building research knowledge, develop human resource as well as provide infrastructure capability in an emergency situation to drive Thailand economic growth and pertain biosecurity for a good health and well-being society of Thai people.
Below are the research focuses of Lab Immunology:
1. Development of simple diagnostic tests for antigens/antibodies relevant to health problems in Thailand and other countries.2. Development of in vitro assays to reduce and/or replace the use of experimental animals.